CN108112253B - 抗癌融合多肽 - Google Patents

抗癌融合多肽 Download PDF

Info

Publication number
CN108112253B
CN108112253B CN201680028941.3A CN201680028941A CN108112253B CN 108112253 B CN108112253 B CN 108112253B CN 201680028941 A CN201680028941 A CN 201680028941A CN 108112253 B CN108112253 B CN 108112253B
Authority
CN
China
Prior art keywords
seq
fusion protein
gpc3
ser
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680028941.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108112253A (zh
Inventor
M·欣纳
R·S·贝莱巴
C·罗特
S·奥威尔
C·施洛瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pieris Pharmaceuticals GmbH
Original Assignee
Pieris Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals GmbH filed Critical Pieris Pharmaceuticals GmbH
Publication of CN108112253A publication Critical patent/CN108112253A/zh
Application granted granted Critical
Publication of CN108112253B publication Critical patent/CN108112253B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201680028941.3A 2015-05-18 2016-05-18 抗癌融合多肽 Active CN108112253B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15167927.1 2015-05-18
EP15167927 2015-05-18
EP16150508.6 2016-01-08
EP16150508 2016-01-08
PCT/EP2016/061071 WO2016184882A1 (en) 2015-05-18 2016-05-18 Anti-cancer fusion polypeptide

Publications (2)

Publication Number Publication Date
CN108112253A CN108112253A (zh) 2018-06-01
CN108112253B true CN108112253B (zh) 2022-09-23

Family

ID=56134305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680028941.3A Active CN108112253B (zh) 2015-05-18 2016-05-18 抗癌融合多肽

Country Status (22)

Country Link
US (2) US10913778B2 (OSRAM)
EP (2) EP4219535A1 (OSRAM)
JP (1) JP6947642B2 (OSRAM)
KR (1) KR102685748B1 (OSRAM)
CN (1) CN108112253B (OSRAM)
AU (1) AU2016262845B2 (OSRAM)
CA (1) CA2980838A1 (OSRAM)
DK (1) DK3298030T5 (OSRAM)
ES (1) ES2938525T3 (OSRAM)
FI (1) FI3298030T3 (OSRAM)
HR (1) HRP20230145T1 (OSRAM)
HU (1) HUE061108T2 (OSRAM)
LT (1) LT3298030T (OSRAM)
MX (1) MX390894B (OSRAM)
PL (1) PL3298030T3 (OSRAM)
RS (1) RS64002B1 (OSRAM)
RU (2) RU2021119777A (OSRAM)
SG (1) SG11201707426SA (OSRAM)
SI (1) SI3298030T1 (OSRAM)
SM (1) SMT202300026T1 (OSRAM)
WO (1) WO2016184882A1 (OSRAM)
ZA (1) ZA201706061B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
DK3292137T3 (da) * 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
AU2016293101B2 (en) 2015-07-15 2022-06-16 Pieris Pharmaceuticals Gmbh Novel proteins specific for LAG-3
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3565843A1 (en) * 2017-01-03 2019-11-13 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
US11814429B2 (en) 2017-01-06 2023-11-14 Crescendo Biologics Limited Single domain antibodies to programmed cell death (PD-1)
JP7225116B2 (ja) * 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
EP3710477A1 (en) * 2017-11-13 2020-09-23 Crescendo Biologics Limited Single domain antibodies that bind to cd137
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
KR20200136949A (ko) 2018-03-26 2020-12-08 4에스체 악티엔게젤샤프트 암 치료를 위한 hdac 억제제 및 cd137 작용제를 포함하는 배합물
PL3830120T3 (pl) * 2018-07-31 2023-10-09 Pieris Pharmaceuticals Gmbh NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1
EP3931209A1 (en) * 2019-02-26 2022-01-05 Pieris Pharmaceuticals GmbH Novel fusion proteins specific for cd137 and gpc3
CA3127973A1 (en) * 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
WO2020208049A1 (en) * 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
PE20220500A1 (es) * 2019-04-23 2022-04-07 Lg Chemical Ltd POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15
US20210009718A1 (en) 2019-06-25 2021-01-14 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN115960242B (zh) * 2021-09-09 2023-10-17 广东东阳光药业股份有限公司 抗癌结合分子及其应用
IL319272A (en) * 2022-09-21 2025-04-01 Seagen Inc ROVEL FUSION protein specific for CD137 and CD228

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ATE299892T1 (de) 1994-05-18 2005-08-15 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
NZ508249A (en) 1998-06-08 2003-02-28 F Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CA2622441A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
ES2354653T3 (es) 2006-08-01 2011-03-16 Pieris Ag Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
ES2562790T3 (es) 2007-07-17 2016-03-08 E. R. Squibb & Sons, L.L.C. Anticuerpos monoclonales contra Glipicano-3
JP5746861B2 (ja) 2007-10-19 2015-07-08 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 哺乳動物のｎｇａｌに結合する抗体及びその使用
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
RU2564125C2 (ru) 2009-12-07 2015-09-27 Пирис Аг Мутеины липокалина 2 человека (lcn2, hngal) с аффинностью для определенной мишени
DK2606061T3 (da) 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh Bindingsproteiner til hepcidin
CA2810359C (en) 2010-09-09 2021-06-22 Pfizer Inc. 4-1bb binding molecules
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
CA2913029A1 (en) * 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
EP3094650A2 (en) * 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multi-specific polypeptide useful for localized tumor immunomodulation
CA2943943C (en) * 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
WO2016120307A1 (en) 2015-01-28 2016-08-04 Pieris Ag Novel proteins specific for angiogenesis
WO2016131804A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
AU2016258977C1 (en) * 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
DK3292137T3 (da) 2015-05-04 2022-10-17 Pieris Pharmaceuticals Gmbh Proteiner specifikke for cd137
BR112017020961A2 (pt) 2015-05-18 2018-07-10 Pieris Pharmaceuticals Gmbh muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
JP2018519803A (ja) 2018-07-26
CN108112253A (zh) 2018-06-01
EP3298030A1 (en) 2018-03-28
BR112017020445A2 (pt) 2018-07-03
LT3298030T (lt) 2023-02-27
US20180148485A1 (en) 2018-05-31
MX390894B (es) 2025-03-21
ES2938525T3 (es) 2023-04-12
ZA201706061B (en) 2022-05-25
RU2017135539A3 (OSRAM) 2019-11-29
US11919931B2 (en) 2024-03-05
HUE061108T2 (hu) 2023-05-28
RS64002B1 (sr) 2023-03-31
CA2980838A1 (en) 2016-11-24
RU2754466C2 (ru) 2021-09-02
HRP20230145T1 (hr) 2023-04-28
EP3298030B1 (en) 2023-01-18
EP4219535A1 (en) 2023-08-02
JP6947642B2 (ja) 2021-10-13
KR102685748B1 (ko) 2024-07-18
DK3298030T5 (en) 2024-10-07
SG11201707426SA (en) 2017-10-30
RU2021119777A (ru) 2021-08-16
AU2016262845A1 (en) 2018-01-04
MX2017014716A (es) 2018-06-28
FI3298030T3 (fi) 2023-02-22
AU2016262845B2 (en) 2020-07-23
US10913778B2 (en) 2021-02-09
RU2017135539A (ru) 2019-06-18
US20210403516A1 (en) 2021-12-30
KR20180002855A (ko) 2018-01-08
WO2016184882A1 (en) 2016-11-24
SMT202300026T1 (it) 2023-03-17
SI3298030T1 (sl) 2023-05-31
DK3298030T3 (en) 2023-02-06
PL3298030T3 (pl) 2023-05-08

Similar Documents

Publication Publication Date Title
CN108112253B (zh) 抗癌融合多肽
CN107636014B (zh) 抗癌融合多肽
RU2628699C2 (ru) Trail r2-специфические мультимерные скаффолды
JP7482488B2 (ja) Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質
JP7476219B2 (ja) Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
HK40053668A (en) Novel fusion protein specific for cd137 and pd-l1
HK40044273A (en) Novel fusion protein specific for cd137 and pd-l1
HK40044273B (en) Novel fusion protein specific for cd137 and pd-l1
BR112017020445B1 (pt) Proteína de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de uma proteína de fusão, uso de uma ou mais proteínas de fusão e composição farmacêutica
HK1249526B (en) Anti-cancer fusion polypeptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant